Analysts’ recommendations on Boston Scientific
Boston Scientific (BSX) is a leading medical technology company in the United States. The company has been a leading player in minimally invasive therapies for a range of cardiovascular and rhythm management diseases, a space that has become increasingly competitive over the years.
Boston Scientific has been expanding in other areas, including endoscopy under its MedSurg business segment. In this space, the company has recently announced the acquisition of EMcision. It has also been investing in the development of innovative endoscopy products. In this article, we’ll discuss analysts’ recent ratings, recommendations, and target prices for BSX stock.
As of March 7, 2018, of 25 Reuters-surveyed analysts covering Boston Scientific, 13 (~52%) recommended “strong buy,” seven (~28%) recommended “buy,” and five (20%) recommended “hold.” There were no “sell” recommendations. For a 12-month recommendation summary on BSX stock, see the above chart.
Wall Street’s consensus price target for BSX stock for the next 12 months is $31.57, implying a return potential of ~15.2% based on the stock’s closing price of $27.41 on March 6, 2018.
Wall Street rating revisions and updates
On February 5, 2018, Citigroup raised its target price on BSX stock from $31 to $32 while maintaining its recommendation on the stock. On February 2, 2018, following the company’s 4Q17 and fiscal 2017 earnings release on February 1, Needham & Company increased its target price on Boston Scientific from $32 to $35, and Jefferies increased its target price from $27 to $29.